Ipratropium bromide/salbutamol
| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Trade names | Combivent, Duoneb, Breva, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601063 |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).[1][4][5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[1]
Common side effects include sore throat, muscle cramps, and nausea.[1] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[1] Safety in pregnancy is unclear.[6][1]
The combination was approved for medical use in the United States in 1996.[7] It is available as a generic medication.[4] In 2022, it was the 178th most commonly prescribed medication in the United States, with more than 2.7 million prescriptions.[8][9]
Medical uses
[edit]Ipratropium bromide/salbutamol can be used for the treatment of COPD[5] and asthma.[10]
Society and culture
[edit]Since Combivent contains a chlorofluorocarbon-based propellant, its use was discontinued in 2013 in the United States and other countries. This is because chlorofluorocarbons are attributed to depletion of the ozone layer.[11]
References
[edit]- ^ a b c d e f "Combivent Respimat- ipratropium bromide and albuterol spray, metered". DailyMed. 24 January 2022. Retrieved 30 October 2022.
- ^ "DuoNeb". DailyMed. Retrieved 30 October 2022.
- ^ "Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol". DailyMed. Retrieved 30 October 2022.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
- ^ a b Gordon J, Panos RJ (March 2010). "Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease". Expert Opinion on Drug Metabolism & Toxicology. 6 (3): 381–92. doi:10.1517/17425251003649549. PMID 20163324. S2CID 31806856.
- ^ "Albuterol / ipratropium Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
- ^ "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 18 April 2019.
- ^ "The Top 200 of 2022". ClinCalc. Archived from the original on 23 August 2024. Retrieved 23 August 2024.
- ^ "Albuterol; Ipratropium - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, et al. (April 2016). "Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial". BMC Pulmonary Medicine. 16 (1): 65. doi:10.1186/s12890-016-0223-3. PMC 4851785. PMID 27130202.
- ^ "Phase Out of Combivent Inhalation Aerosol - Questions and Answers". FDA. 3 November 2018.
| α1 |
| ||||
|---|---|---|---|---|---|
| α2 |
| ||||
| β |
| ||||
| mAChRs |
| ||||
|---|---|---|---|---|---|
| Precursors (and prodrugs) | |||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
